as mentioned in A prime-boost Ebola vaccine regimen that is well into clinical trials shows immune response 1 year after vaccination, the longest so far for experimental vaccines against the disease using that strategy, researchers reported today.
The team had previously shown that the immune response to Ebola persisted for 8 months.
They included the caveat that one limitation of their study is that it was conducted in a European population, in whom immune response might differ from populations in sub-Saharan Africa.
All of the vaccine recipients maintained Ebola-specific immunoglobulin G response at day 360.
World Health Organization (WHO) advisors have said different types of vaccines will likely be needed to protect people against Ebola.
Two-part Ebola vaccine offers long-lasting protection
That is different from another Ebola vaccine from Merck, which was the first to prove effective in preventing human infection during a large trial in Guinea last year.
The findings, based on a Phase I clinical trial involving 75 healthy subjects, were published in the Journal of the American Medical Association.
(Reuters) – The world should be far better prepared for the next Ebola outbreak, with further promising results on Tuesday showing the potential of a long-lasting vaccine against the deadly virus.
The vaccine requires one dose to prime the immune system and a second shot to boost the body’s response.
Scientists have been racing to develop vaccines for Ebola after more than 11,300 people died in West Africa’s 2013-2016 epidemic.
Ebola vaccine trial for great apes shows promise –
Now, a vaccine trial on a small number of captive apes in the United States shows promise in addressing the dangers of Ebola virus disease (EVD) within this vector.
The Filorab1 vaccine inserts the gene encoding the Ebola glycoprotein (GP) into a replication of a previously tested rabies (RABV) vaccine.
By Alexandra Simon-LewisIn March 2014, West Africa became ground zero for the largest Ebola outbreak in history.
This was due to the high safety and effectiveness of the parent rabies vaccine in previous oral trials.
The study, published in the journal Scientific Reports, used an oral Filorab1 vaccine on a group of ten captive chimpanzees at the University of Louisiana Lafayette in the US.
This content may collect you by Victoria Hunter